HIV-1 and HSV-2 were suppressi

United States academic studies suggest that for type 1 human immunodeficiency virus (HIV-1) and herpes simplex virus type 2 (HSV-2) co-infection of patients, in front of the starting antiretroviral treatment, inhibiting HSV-2 can slow the disease progression of HIV-1 infection.　　　Related papers online February 15, 2010, published in the Lancet (Lancet) magazine. The multicenter, double-blind, exploratory testing into 14 medical institutions in Eastern and southern Africa 3,381 cases of double infection in patients with HSV-2 and HIV-1. Selected subjects of the CD4 cell count ≥ 250/μ l, antiretroviral therapy does not start. Its average random grouping, respectively to acyclovir (400 mg,bid) orally or placebo, follow-up of 24 months.　　　Assess the effect of acyclovir on delaying HIV-1 infection progress primary composite end point: first CD4 cell counts less than 200/μ l, starting antiretroviral treatment, no trauma-related deaths. Turns out, in a group with the median CD4 cell count is 462/μ l, HIV-1 as 4.1log10 copies/μ l plasma RNA levels. Acyclovir HIV-1 16% reduction in risk of disease progression, treatment group, control group of 324 cases reached the Primary endpoint of 284 cases [risk ratio (HR) is 0.84]. In patients with CD4 ≥ 350/μ l, effects on luoweike CD4 counts dropped to < 350/μ l reduce the risk of 19% (HR=0.81,P=0.002). www.cmt.com.cn